ValGenesis to Highlight Process Validation Shift at BioProcessing Summit Europe
Event summary
- ValGenesis will showcase its Process Lifecycle Suite at BioProcessing Summit Europe 2026, March 10-12 in Barcelona.
- The summit focuses on bioprocessing innovation and decision-makers in modern biomanufacturing.
- ValGenesis's Process Lifecycle Suite is part of the broader ValGenesis Smart GxP™ platform.
- Many biopharma companies, including cell and gene therapy developers, are using siloed systems for process lifecycle management.
- Steve Reynolds, Chief Revenue Officer at ValGenesis, emphasized the ongoing nature of process validation.
The big picture
The biopharmaceutical industry, particularly cell and gene therapy, faces mounting pressure to streamline and digitize process validation, a historically manual and complex undertaking. ValGenesis's focus on a connected, end-to-end lifecycle strategy addresses a critical pain point for companies struggling with compliance and scalability. The shift towards digital validation represents a significant opportunity to reduce costs, accelerate drug development, and improve overall process control within a rapidly expanding market.
What we're watching
- Governance Dynamics
- The adoption rate of integrated lifecycle management platforms will likely be tied to increasing regulatory scrutiny and demand for real-time process oversight, particularly within cell and gene therapy manufacturing.
- Execution Risk
- ValGenesis's success hinges on its ability to demonstrate tangible ROI for clients transitioning from fragmented, manual validation processes, which may require significant organizational change management.
- Regulatory Headwinds
- The evolving regulatory landscape surrounding continuous process verification (CPV) and process validation will continue to drive demand for digital solutions, but also necessitate ongoing platform adaptation and validation.
Related topics